A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

BACKGROUND: Vilazodone, a selective serotonin reuptake inhibitor and 5-HT(1A) receptor partial agonist, is approved for treating major depressive disorder in adults. This study (NCT01629966 ClinicalTrials.gov) evaluated the efficacy and safety of vilazodone in adults with generalized anxiety disorde...

Descripción completa

Detalles Bibliográficos
Autores principales: Gommoll, Carl, Durgam, Suresh, Mathews, Maju, Forero, Giovanna, Nunez, Rene, Tang, Xiongwen, Thase, Michael E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676920/
https://www.ncbi.nlm.nih.gov/pubmed/25891440
http://dx.doi.org/10.1002/da.22365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676920/
https://www.ncbi.nlm.nih.gov/pubmed/25891440
http://dx.doi.org/10.1002/da.22365

Ejemplares similares